组蛋白赖氨酸乳酰化（Kla）诱导的BCAM促进口腔鳞状细胞癌进展和顺铂耐药。

Histone Lysine Lactylation (Kla)-induced BCAM Promotes OSCC Progression and Cis-Platinum Resistance.

作者信息

Huang Guangzhao, Chen Su, He Jialu, Li Honglin, Ma Zhongkai, Lubamba Grace Paka, Wang Lei, Guo Zhiyong, Li Chunjie

机构信息

State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Frontier Innovation Center for Dental Medicine Plus, Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Department of Dentistry, The Second people's Hospital of Tibet Autonomous Region, Xizang, China.

出版信息

Oral Dis. 2025 Apr;31(4):1116-1132. doi: 10.1111/odi.15179. Epub 2024 Nov 6.

DOI:10.1111/odi.15179

PMID:39503345

Abstract

OBJECTIVE

Histone lysine lactylation (Kla) plays a vital role in cancer progression. However, the prognostic value of histone Kla in oral squamous cell carcinoma (OSCC) remains unclear.

MATERIALS AND METHODS

OSCC RNA expression data were obtained from the TCGA and GEO databases. We explored the prognostic value of histone Kla in OSCC via constructing a Cox model and determined the role of Kla in OSCC drug susceptibility and tumor microenvironment (TME). In addition, the biological roles of candidate biomarkers were identified.

RESULTS

A total of 1223 Kla-specific genes were obtained, with 228 DEKlaGs in OSCC. GO and KEGG enrichment analyses suggested that DEKlaGs contributed to inflammatory and cancer progression. A Cox model in accordance with BCAM, CGNL1, DGKG, and OLR1 could predict OSCC patient prognosis accurately. Subsequently, Kla-induced prognostic genes were identified to play a crucial role in OSCC drug therapy and TME. Moreover, BCAM was identified as a biomarker that promoted OSCC invasion, angiogenesis, and chemotherapy resistance.

CONCLUSION

Kla was identified to be associated with OSCC prognosis, drug therapy, and TME. Histone Kla-induced BCAM was identified to play a crucial role during OSCC progression, suggesting that Kla is promising to be a novel therapeutic target for OSCC.

摘要

目的

组蛋白赖氨酸乳酰化（Kla）在癌症进展中起重要作用。然而，组蛋白Kla在口腔鳞状细胞癌（OSCC）中的预后价值仍不清楚。

材料与方法

从TCGA和GEO数据库获取OSCC RNA表达数据。我们通过构建Cox模型探索组蛋白Kla在OSCC中的预后价值，并确定Kla在OSCC药物敏感性和肿瘤微环境（TME）中的作用。此外，还鉴定了候选生物标志物的生物学作用。

结果

共获得1223个Kla特异性基因，其中OSCC中有228个差异表达的Kla基因（DEKlaGs）。GO和KEGG富集分析表明，DEKlaGs促进炎症和癌症进展。基于BCAM、CGNL1、DGKG和OLR1的Cox模型能够准确预测OSCC患者的预后。随后，鉴定出Kla诱导的预后基因在OSCC药物治疗和TME中起关键作用。此外，BCAM被鉴定为促进OSCC侵袭、血管生成和化疗耐药的生物标志物。